These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15750833)

  • 41. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A.
    Yu YZ; Zhang SM; Sun ZW; Wang S; Yu WY
    Vaccine; 2007 Dec; 25(52):8843-50. PubMed ID: 18022294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune responses in mice vaccinated with a suicidal DNA vaccine expressing the hemagglutinin glycoprotein from the peste des petits ruminants virus.
    Wang Y; Liu G; Shi L; Li W; Li C; Chen Z; Jin H; Xu B; Li G
    J Virol Methods; 2013 Nov; 193(2):525-30. PubMed ID: 23896018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.
    Walczak M; de Mare A; Riezebos-Brilman A; Regts J; Hoogeboom BN; Visser JT; Fiedler M; Jansen-Dürr P; van der Zee AG; Nijman HW; Wilschut J; Daemen T
    Mol Pharm; 2011 Feb; 8(1):65-77. PubMed ID: 20825215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
    Lee SW; Li H; Strong TV; Moore SE; Conry RM
    J Immunother; 2000; 23(3):379-86. PubMed ID: 10838667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
    Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
    Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis.
    Yin X; Wang W; Zhu X; Wang Y; Wu S; Wang Z; Wang L; Du Z; Gao J; Yu J
    Biochem Biophys Res Commun; 2015 Sep; 465(2):239-44. PubMed ID: 26253468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.
    Knudsen ML; Mbewe-Mvula A; Rosario M; Johansson DX; Kakoulidou M; Bridgeman A; Reyes-Sandoval A; Nicosia A; Ljungberg K; Hanke T; Liljeström P
    J Virol; 2012 Apr; 86(8):4082-90. PubMed ID: 22318135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
    Zhou C; Peng G; Jin X; Tang J; Chen Z
    Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
    Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
    J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
    Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
    Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
    Valmori D; Lévy F; Miconnet I; Zajac P; Spagnoli GC; Rimoldi D; Liénard D; Cerundolo V; Cerottini JC; Romero P
    J Immunol; 2000 Jan; 164(2):1125-31. PubMed ID: 10623865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.
    Niedre-Otomere B; Bogdanova A; Skrastina D; Zajakina A; Bruvere R; Ose V; Gerlich WH; Garoff H; Pumpens P; Glebe D; Kozlovska T
    J Viral Hepat; 2012 Sep; 19(9):664-73. PubMed ID: 22863271
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice.
    Lyons JA; Sheahan BJ; Galbraith SE; Mehra R; Atkins GJ; Fleeton MN
    Gene Ther; 2007 Mar; 14(6):503-13. PubMed ID: 17167497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses.
    Ligtenberg MA; Rojas-Colonelli N; Kiessling R; Lladser A
    Hum Vaccin Immunother; 2013 Oct; 9(10):2189-95. PubMed ID: 23884215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.